1
|
Legrand P, Dufaÿ S, Mignet N, Houzé P, Gahoual R. Modeling study of long-term stability of the monoclonal antibody infliximab and biosimilars using liquid-chromatography-tandem mass spectrometry and size-exclusion chromatography-multi-angle light scattering. Anal Bioanal Chem 2023; 415:179-192. [PMID: 36449030 PMCID: PMC9709354 DOI: 10.1007/s00216-022-04396-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Revised: 10/07/2022] [Accepted: 10/20/2022] [Indexed: 12/02/2022]
Abstract
Monoclonal antibodies (mAbs) represent a dynamic class of biopharmaceutical products, as evidenced by an increasing number of market authorizations for mAb innovator and biosimilar products. Stability studies are commonly performed during product development, for instance, to exclude unstable molecules, optimize the formulation or determine the storage limit. Such studies are time-consuming, especially for mAbs, because of their structural complexity which requires multiple analytical techniques to achieve a detailed characterization. We report the implementation of a novel methodology based on the accelerated stability assessment program (ASAP) in order to model the long-term stability of mAbs in relation to different structural aspects. Stability studies of innovator infliximab and two different biosimilars were performed using forced degradation conditions alongside in-use administration conditions in order to investigate their similarity regarding stability. Thus, characterization of post-translational modifications was achieved using liquid-chromatography-tandem mass spectrometry (LC-MS/MS) analysis, and the formation of aggregates and free chain fragments was characterized using size-exclusion chromatography-multi-angle light scattering (SEC-MALS-UV/RI) analysis. Consequently, ASAP models were investigated with regard to free chain fragmentation of mAbs concomitantly with N57 deamidation, located in the hypervariable region. Comparison of ASAP models and the long-term stability data from samples stored in intravenous bags demonstrated a relevant correlation, indicating the stability of the mAbs. The developed methodology highlighted the particularities of ASAP modeling for mAbs and demonstrated the possibility to independently consider the different types of degradation pathways in order to provide accurate and appropriate prediction of the long-term stability of this type of biomolecule.
Collapse
Affiliation(s)
- Pauline Legrand
- Université Paris Cité, Faculté de sciences pharmaceutiques et biologiques, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), CNRS UMR8258, Inserm U1267, 4, avenue de l'observatoire, 75270, Paris Cedex 06, France.
- Département Recherche Et Développement Pharmaceutique, Agence Générale Des Equipements Et Produits de Santé (AGEPS), Assistance Publique-Hôpitaux de Paris, (AP-HP), Paris, France.
| | - Sophie Dufaÿ
- Département Recherche Et Développement Pharmaceutique, Agence Générale Des Equipements Et Produits de Santé (AGEPS), Assistance Publique-Hôpitaux de Paris, (AP-HP), Paris, France
| | - Nathalie Mignet
- Université Paris Cité, Faculté de sciences pharmaceutiques et biologiques, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), CNRS UMR8258, Inserm U1267, 4, avenue de l'observatoire, 75270, Paris Cedex 06, France
| | - Pascal Houzé
- Université Paris Cité, Faculté de sciences pharmaceutiques et biologiques, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), CNRS UMR8258, Inserm U1267, 4, avenue de l'observatoire, 75270, Paris Cedex 06, France
- Laboratoire de Toxicologie Biologique, Hôpital Lariboisière, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Rabah Gahoual
- Université Paris Cité, Faculté de sciences pharmaceutiques et biologiques, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), CNRS UMR8258, Inserm U1267, 4, avenue de l'observatoire, 75270, Paris Cedex 06, France
| |
Collapse
|
2
|
Boiteau JG, Mouis G, Reverse K, Surget E, Boccadifuoco G, Dufaÿ S. Complete 1 H, 13 C, and 15 N assignments of the minor isomer of codeine N-oxide. Magn Reson Chem 2022; 60:1185-1188. [PMID: 35919948 DOI: 10.1002/mrc.5302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/17/2022] [Revised: 07/25/2022] [Accepted: 07/27/2022] [Indexed: 06/15/2023]
Abstract
Codeine N-oxide 2 is an active metabolite of codeine obtained by oxidation and observed as a degradant in codeine drug products such as syrups. Oxidation of codeine's N-methyl function can deliver two regio-isomers due to chirality of the tetra-substituted nitrogen. Hydrogen peroxide oxidation of codeine was performed and induced two different isomers in a 9:1 ratio; these isomers were isolated using preparative high performance liquid chromatography (HPLC) and fully characterized by nuclear magnetic resonance (NMR) techniques. We describe the complete assignment of the minor isomer of codeine N-oxide 3 and attribute a (S) configuration (N-methyl axial) of the tetra-substituted nitrogen. The effects of N-oxidation on the 15 N chemical shifts of the codeine are presented. The 15 N shifts were determined using the CIGAR-HMBC experiment at natural abundance, and the nitrogen resonance of codeine shifted downfield from 42.8 to 118.7 ppm for both N-oxide isomers.
Collapse
Affiliation(s)
| | | | - Kevin Reverse
- Chemical Development, Nuvisan, Sophia-Antipolis, France
| | - Estelle Surget
- Département de Recherche et Développement Pharmaceutique (DRDP), AP-HP, Agence Générale des Equipements et produits de Santé (AGEPS), Paris, France
| | - Gaetan Boccadifuoco
- Département de Recherche et Développement Pharmaceutique (DRDP), AP-HP, Agence Générale des Equipements et produits de Santé (AGEPS), Paris, France
| | - Sophie Dufaÿ
- Département de Recherche et Développement Pharmaceutique (DRDP), AP-HP, Agence Générale des Equipements et produits de Santé (AGEPS), Paris, France
| |
Collapse
|
3
|
Legrand P, Gahoual R, Houzé P, Dufaÿ S. Accelerated Stability Assessment Program to Predict Long-term Stability of Drugs: Application to Ascorbic Acid and to a Cyclic Hexapeptide. AAPS PharmSciTech 2021; 22:234. [PMID: 34498167 DOI: 10.1208/s12249-021-02121-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2021] [Accepted: 08/13/2021] [Indexed: 11/30/2022] Open
Abstract
During pharmaceutical development, the stability of the product is assessed during long-term study. If any stability issues are discovered at this point of the process, it will result in re-formulation and important loss of time and cost. Therefore, important efforts are made in order to select the most stable product. Nevertheless, predicting the stability of the developed product at early stage of the development is challenging. Accelerated stability assessment program (ASAP), based on modified Arrhenius equation and isoconversion approach, appears as an interesting tool allowing to evaluate stability and shelf-life of pharmaceutical product in a short period of time. Nevertheless, few studies using these approaches are published in the literature, and the majority concern small drug molecules. Here, this approach was applied on a small drug molecule, ascorbic acid (AA), and on a cyclic hexapeptide named cFEE. AA and cFEE have been exposed to various temperatures for a maximum of 3 weeks, and then analyzed by capillary electrophoresis coupled to UV detection (CZE-UV) for AA or LC-MS for cFEE. The level of major degradation products was used to build ASAP models and predict the stability of both compounds. Comparison between predicted and long-term data were found accurate for both compounds undergoing two different degradation pathways (oxidation and hydrolysis), confirming the real interest of accelerated predicting stability approach for consistent determination of long-term stability shelf-life of pharmaceutical products.
Collapse
|
4
|
Annereau M, Toussaint B, Dufaÿ Wojcicki A, Dufaÿ S, Diaz Salmeron R, Boudy V. [2D-3D printing in hospital pharmacies, what roles and challenges?]. Ann Pharm Fr 2021; 79:361-374. [PMID: 33515591 DOI: 10.1016/j.pharma.2021.01.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2020] [Revised: 01/06/2021] [Accepted: 01/12/2021] [Indexed: 10/22/2022]
Abstract
The additive technology or 2D and 3D printing are increasingly used in various industrial fields, from aeronautics to mechanics but also in the fields of health such as dentistry or for bone reconstructions. These techniques have been studied for about fifteen years by the academic community in the pharmaceutical field (medical device and drug), and recently they have started to be applied to produce drugs in industry and in hospitals. Indeed, the Food and Drug Administration approved in August 2015 the marketing of the first drug printed by additive technique, then in 2018 the first clinical trial using 3D printed drugs was carried out in Great Britain by a hospital pharmacy. 2D-3D printing is presented as one of the tools of a more personalized medicine, the techniques of additive printing allowing the production of tabs containing several drugs in one tab (polypills) and the development of custom modified-releases drugs. This approach could allow better acceptance of the finished product and secure manufacturing. The objective of this work is to highlight relevant printing technologies for implementation in hospital pharmacies, and to see how these technologies could lead to a change in pharmaceutical practices, to improve patient care.
Collapse
Affiliation(s)
- M Annereau
- Département recherche et développement pharmaceutique, Agencegénérale des équipements et produits de santé (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), 7, rue du Fer-à-Moulin, 75005 Paris, France
| | - B Toussaint
- Département recherche et développement pharmaceutique, Agencegénérale des équipements et produits de santé (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), 7, rue du Fer-à-Moulin, 75005 Paris, France; Université de Paris, CNRS, Inserm, UTCBS, Unité des technologies chimiques et biologiques pour la santé, 75006 Paris, France
| | - A Dufaÿ Wojcicki
- Département recherche et développement pharmaceutique, Agencegénérale des équipements et produits de santé (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), 7, rue du Fer-à-Moulin, 75005 Paris, France
| | - S Dufaÿ
- Département recherche et développement pharmaceutique, Agencegénérale des équipements et produits de santé (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), 7, rue du Fer-à-Moulin, 75005 Paris, France
| | - R Diaz Salmeron
- Département recherche et développement pharmaceutique, Agencegénérale des équipements et produits de santé (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), 7, rue du Fer-à-Moulin, 75005 Paris, France
| | - V Boudy
- Département recherche et développement pharmaceutique, Agencegénérale des équipements et produits de santé (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), 7, rue du Fer-à-Moulin, 75005 Paris, France; Université de Paris, CNRS, Inserm, UTCBS, Unité des technologies chimiques et biologiques pour la santé, 75006 Paris, France.
| |
Collapse
|
5
|
Destruel PL, Zeng N, Brignole-Baudouin F, Douat S, Seguin J, Olivier E, Dutot M, Rat P, Dufaÿ S, Dufaÿ-Wojcicki A, Maury M, Mignet N, Boudy V. In Situ Gelling Ophthalmic Drug Delivery System for the Optimization of Diagnostic and Preoperative Mydriasis: In Vitro Drug Release, Cytotoxicity and Mydriasis Pharmacodynamics. Pharmaceutics 2020; 12:E360. [PMID: 32326492 PMCID: PMC7238180 DOI: 10.3390/pharmaceutics12040360] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2020] [Revised: 04/08/2020] [Accepted: 04/13/2020] [Indexed: 11/16/2022] Open
Abstract
Mydriasis is required prior to many eye examinations and ophthalmic surgeries. Nowadays, phenylephrine hydrochloride (PHE) and tropicamide (TPC) are extensively used to induce mydriasis. Several pharmaceutic dosage forms of these two active ingredients have been described. However, no optimal therapeutic strategy has reached the market. The present work focuses on the formulation and evaluation of a mucoadhesive ion-activated in situ gelling delivery system based on gellan gum and hydroxyethylcellulose (HEC) for the delivery of phenylephrine and tropicamide. First, in vitro drug release was studied to assess appropriate sustained drug delivery on the ocular surface region. Drug release mechanisms were explored and explained using mathematical modeling. Then, in situ gelling delivery systems were visualized using scanning electron microscopy illustrating the drug release phenomena involved. Afterward, cytotoxicity of the developed formulations was studied and compared with those of commercially available eye drops. Human epithelial corneal cells were used. Finally, mydriasis intensity and kinetic was investigated in vivo. Mydriasis pharmacodynamics was studied by non-invasive optical imaging on vigilant rabbits, allowing eye blinking and nasolacrimal drainage to occur physiologically. In situ gelling delivery systems mydriasis profiles exhibited a significant increase of intensity and duration compared with those of conventional eye drops. Efficient mydriasis was achieved following the administration of a single drop of in situ gel reducing the required amount of administered active ingredients by four- to eight-fold compared with classic eye drop regimen.
Collapse
Affiliation(s)
- Pierre-Louis Destruel
- Unither Développement Bordeaux, ZA Tech Espace, av Toussaint Catros, 33185 Le Haillan, France;
- Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 7 rue du fer à moulin, 75005 Paris, France (V.B.)
- Université de Paris, UTCBS, CNRS, INSERM, Faculté de Pharmacie, 4 av de l’observatoire, 75006 Paris, France
| | - Ni Zeng
- Unither Pharmaceuticals, 3-5 rue St-Georges, 75009 Paris, France
| | - Françoise Brignole-Baudouin
- UMR CNRS 8038-Chimie Toxicologie Analytique et Cellulaire, 75006 Paris, France
- CNRS UMR 7210-Inserm UMR_S 968, Institut de la Vision, 75012 Paris, France
- Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, INSERM-DHOS, CIC 503, 75012 Paris, France
| | - Sophie Douat
- Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 7 rue du fer à moulin, 75005 Paris, France (V.B.)
| | - Johanne Seguin
- Université de Paris, UTCBS, CNRS, INSERM, Faculté de Pharmacie, 4 av de l’observatoire, 75006 Paris, France
| | - Elodie Olivier
- UMR CNRS 8038-Chimie Toxicologie Analytique et Cellulaire, 75006 Paris, France
| | - Melody Dutot
- UMR CNRS 8038-Chimie Toxicologie Analytique et Cellulaire, 75006 Paris, France
- Recherche et Développement, Laboratoire d’Evaluation Physiologique, Yslab, 2 rue Félix le Dantec, 29000 Quimper, France
| | - Patrice Rat
- UMR CNRS 8038-Chimie Toxicologie Analytique et Cellulaire, 75006 Paris, France
| | - Sophie Dufaÿ
- Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 7 rue du fer à moulin, 75005 Paris, France (V.B.)
| | - Amélie Dufaÿ-Wojcicki
- Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 7 rue du fer à moulin, 75005 Paris, France (V.B.)
| | - Marc Maury
- Unither Pharmaceuticals, 3-5 rue St-Georges, 75009 Paris, France
| | - Nathalie Mignet
- Université de Paris, UTCBS, CNRS, INSERM, Faculté de Pharmacie, 4 av de l’observatoire, 75006 Paris, France
| | - Vincent Boudy
- Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 7 rue du fer à moulin, 75005 Paris, France (V.B.)
- Université de Paris, UTCBS, CNRS, INSERM, Faculté de Pharmacie, 4 av de l’observatoire, 75006 Paris, France
| |
Collapse
|
6
|
Destruel PL, Zeng N, Seguin J, Douat S, Rosa F, Brignole-Baudouin F, Dufaÿ S, Dufaÿ-Wojcicki A, Maury M, Mignet N, Boudy V. Novel in situ gelling ophthalmic drug delivery system based on gellan gum and hydroxyethylcellulose: Innovative rheological characterization, in vitro and in vivo evidence of a sustained precorneal retention time. Int J Pharm 2019; 574:118734. [PMID: 31705970 DOI: 10.1016/j.ijpharm.2019.118734] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2019] [Revised: 09/20/2019] [Accepted: 09/24/2019] [Indexed: 12/15/2022]
Abstract
Achieving drug delivery at the ocular level encounters many challenges and obstacles. In situ gelling delivery systems are now widely used for topical ocular administration and recognized as a promising strategy to improve the treatment of a wide range of ocular diseases. The present work describes the formulation and evaluation of a mucoadhesive and ion-activated in situ gelling delivery system based on gellan gum and hydroxyethylcellulose for the delivery of phenylephrine and tropicamide. First, physico-chemical characteristics were assessed to ensure suitable properties regarding ocular administration. Then, rheological properties such as viscosity and gelation capacity were determined. Gelation capacity of the formulations and the effect of hydroxyethylcellulose on viscosity were demonstrated. A new rheological method was developed to assess the gel resistance under simulated eye blinking. Afterward, mucoadhesion was evaluated using tensile strength test and rheological synergism method in both rotational and oscillatory mode allowing mucoadhesive properties of hydroxyethylcellulose to be point out. Finally, residence time on the ocular surface was investigated in vivo, using cyanine 5.5 dye as a fluorescent marker entrapped in the in situ gelling delivery systems. Residence performance was studied by non-invasive optical imaging on vigilant rabbits, allowing eye blinking and nasolacrimal drainage to occur physiologically. Fluorescence intensity profiles pointed out a prolonged residence time on the ocular surface region for the developed formulations compared to conventional eye drops, suggesting in vitro / in vivo correlations between rheological properties and in vivo residence performances.
Collapse
Affiliation(s)
- Pierre-Louis Destruel
- Unither Développement Bordeaux, ZA Tech Espace, av Toussaint Catros, Le Haillan 33185, France; Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 7 rue du fer à moulin, Paris 75005, France; Université de Paris, UTCBS, CNRS, INSERM, Faculté de Pharmacie, 4 av de l'observatoire, Paris 75006, France(1)
| | - Ni Zeng
- Unither Pharmaceuticals, 3-5 rue St-Georges, Paris 75009, France
| | - Johanne Seguin
- Université de Paris, UTCBS, CNRS, INSERM, Faculté de Pharmacie, 4 av de l'observatoire, Paris 75006, France(1)
| | - Sophie Douat
- Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 7 rue du fer à moulin, Paris 75005, France
| | - Frédéric Rosa
- Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 7 rue du fer à moulin, Paris 75005, France
| | - Françoise Brignole-Baudouin
- UMR CNRS 8638 - Chimie Toxicologie Analytique et Cellulaire, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Pharmacie de Paris, 4 Avenue de l'Observatoire, Paris 75006, France; CNRS UMR 7210 - Inserm UMR_S 968, Institut de la Vision, Paris, 75012, France; Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, INSERM-DHOS, CIC 503, Paris, 75012, France
| | - Sophie Dufaÿ
- Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 7 rue du fer à moulin, Paris 75005, France
| | - Amélie Dufaÿ-Wojcicki
- Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 7 rue du fer à moulin, Paris 75005, France
| | - Marc Maury
- Unither Pharmaceuticals, 3-5 rue St-Georges, Paris 75009, France
| | - Nathalie Mignet
- Université de Paris, UTCBS, CNRS, INSERM, Faculté de Pharmacie, 4 av de l'observatoire, Paris 75006, France(1)
| | - Vincent Boudy
- Département Recherche et Développement Pharmaceutique, Agence Générale des Equipements et Produits de Santé (AGEPS), AP-HP, 7 rue du fer à moulin, Paris 75005, France; Université de Paris, UTCBS, CNRS, INSERM, Faculté de Pharmacie, 4 av de l'observatoire, Paris 75006, France(1).
| |
Collapse
|